





To the Editor: Nonpandemic 
infectious diseases occur with usual 
incidence during pandemics even 
though clinical attention is often on 
the pandemic pathogen. Many of 
these other infectious diseases share 
similar clinical signs and symptoms 
and are sometimes fatal. During the 
outbreak of pandemic (H1N1) 2009, 
tissue specimens from case-patients 
with undiagnosed fatal respiratory 
illnesses were submitted to the 
Infectious Diseases Pathology Branch 
at the Centers for Disease Control and 
Prevention (Atlanta, Georgia, USA) 
for evaluation for pandemic (H1N1) 
2009 virus infection (1).
All respiratory tissue specimens 
from 450 case-patients received 
during April 29, 2009–May 5, 2010, 
were screened by the Centers for 
Disease Control and Prevention 
real-time reverse transcription PCR 
(rRT-PCR) protocol for detection and 
characterization of swine infl uenza 
virus (2). Of these, specimens from 250 
(56%) tested negative for pandemic 
(H1N1) 2009 virus and had no other 
confi rmatory or prior infl uenza testing. 
Of these case-patients whose specimens 
tested negative for pandemic (H1N1) 
2009 virus, a total of 139 (56%) were 
male, and the median age was 30 
years (range 8 days to 81 years). The 
median duration from onset of illness 
to death was 7 days (range 1–40 days). 
Of the 164 case-patients with available 
medical records, 127 (77%) had >1 
underlying or preexisting medical 
condition.
When compared with case-
patients during the same time who had 
pandemic (H1N1) 2009 virus infection 
confi rmed by rRT-PCR, case-patients 
who were not infected with pandemic 
(H1N1) 2009 virus were more likely to 
be young (<9 years of age; odds ratio 
[OR] 2.23, 95% confi dence interval 
[CI] 1.38–3.61) and less likely to be 
obese (OR 0.6, 95% CI 0.36–0.92) or 
have asthma (OR 0.33, 95% CI 0.16–
0.68). Fever, cough, and shortness of 
breath were less frequently reported 
in the case-patients without pandemic 
(H1N1) 2009.
On the basis of the histopathologic 
features observed in the respiratory 
tissues of the case-patients who were 
not infected with pandemic (H1N1) 
2009, along with their clinical and 
epidemiologic information, the 
specimens were further evaluated by 
using special histochemical stains, 
immunohistochemical tests, and 
molecular assays. At least l etiologic 
agent was identifi ed in specimens from 
69 (28%) of the 250 specimens (Table). 
Bacterial pathogens were identifi ed 
for 44 case-patients; Staphylococcus 
aureus and Streptococcus pneumoniae 
were the most frequently identifi ed. 
Immunohistochemical tests and 
PCRs found evidence of viral agents 
in samples from 26 case-patients. 
Most of these were seasonal or 
unsubtypeable infl uenza A viruses; 
in a smaller subset, other respiratory 
viruses were detected, including 
respiratory syncytial virus and 
adenovirus. Multiple fungal pathogens 
were detected in specimens from 2 
case-patients.
For many of the diseases caused by 
the pathogens subsequently identifi ed, 
the clinical features are predominantly 
respiratory, and many nonspecifi c 
manifestations are similar to those 
of infl uenza. Nonetheless, >50% of 
the patients in this study who died 
of suspected infl uenza had negative 
test results for pandemic (H1N1) 
2009 virus, and for >25% of these, 
other infectious causes were detected. 
Infections other than infl uenza should 
be considered during a pandemic 
and during an endemic infl uenza 
season to facilitate the diagnosis of 
illness and treatment of patients with 
complications or severe respiratory 
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Table. Infectious agents identified in tissue samples from case-patients without 
pandemic (H1N1) 2009 virus infection, United States, 2009 
Agent No. case-patients* 
Bacterial 44
 Staphylococcus aureus 14
 Streptococcus pneumoniae 14
 Streptococcus pyogenes 4
Streptococcus viridans group 4
 Leptospira spp. 2
 Clostridium perfringens 1
 Capnocytophaga canimorsus 1
 Haemophilus influenzae 1
 Legionella spp. 1
 Neisseria meningitidis 1
 Pseudomonas spp. 1
 Rickettsia rickettsii 1
 Streptococcus agalactiae 1
Viral 25
 Influenza A, unsubtypeable† 10
 Influenza A, seasonal (H1/H3) 6
 Respiratory syncytial virus 3
 Dengue virus 2
 Enterovirus 2
 Adenovirus 1
 Human herpes virus 1 1
Fungal 2
 Aspergillus spp. 2
 Candida spp. 2
*For some case-patients, multiple agents were detected. 
†Subtype not determined by 2 assays, including 1 specific for pandemic (H1N1) 2009 (2).
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infections. Although we did not 
conduct a case–control study, these 
fi ndings also support the results of 
other studies that previously reported 
the demographic characteristics of 
patients with pandemic infl uenza 
infections and the risk factors for 
severe or fatal pandemic infl uenza 
infections (3,4), especially with 
respect to obesity (5).
Evaluation of tissues collected 
during autopsy from patients with 
a suspected infectious process can 
provide an etiologic diagnosis that 
was not available from routine 
premortem and postmortem testing. 
Other etiologic agents detected in 
this study included reportable disease 
agents (e.g., Rickettsia rickettsii, 
Legionella pneumophila, dengue 
virus), vaccine-preventable diseases 
(e.g., pneumococcal, meningococcal 
diseases), and zoonotic agents 
(Leptospira and Capnocytophaga 
spp.). These fi ndings underscore the 
need for autopsies for diagnosing 
fatal infectious diseases (6). They 
also confi rm the need for coordinated 
surveillance programs that identify 
deaths potentially attributable to 
infectious causes, including the 
unexplained deaths program (7) and 
medical examiner infectious diseases 
death surveillance program (8). 
Partnerships of medical examiners 
and pathologists with local, state, and 
federal public health departments are 
crucial for detecting and monitoring 
pandemic diseases and for assessing 
the scope and magnitude of infectious 
agents that continuously affect human 
populations (9). These infections often 
result in sudden or unexplained death; 
thus, a standardized approach to death 
investigations is recommended.
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To the Editor: In 2010, the 
city of Ngaoundéré in Cameroon 
experienced its fi rst reported epidemic 
of meningococcal meningitis. 
Ngaoundéré, with an estimated 
population of 180,000, is the main city 
in the Adamaoua region in northern 
Cameroon. The 2 northernmost regions 
of Cameroon, North and Far North, 
are considered to belong to the African 
meningitis belt (1) and are periodically 
affected by meningococcal meningitis 
outbreaks. However, the Adamaoua 
region had been spared because of its 
altitude, latitude, and low population 
density in comparison with the North 
and Far North regions. Fewer than 10 
sporadic cases have been reported in 
the Adamaoua region every year.
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